[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638048":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":10,"centralContacts":35,"locations":41,"responsibleParty":56,"collaborators":10,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":10,"enrollmentInfo":67,"targetDuration":70,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":10,"overallStatus":78,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Beijing Anzhen Hospital","OTHER",[8,13,17,21],{"label":9,"type":10,"description":10,"interventionNames":11},"Transcatheter Aortic Valve Replacement",null,[12],"Device: Transcatheter Aortic Valve Replacement",{"label":14,"type":10,"description":10,"interventionNames":15},"Transcatheter Edge-to-Edge Repair",[16],"Device: Transcatheter Edge-to-Edge Repair",{"label":18,"type":10,"description":10,"interventionNames":19},"Transcatheter Tricuspid Valve Annuloplasty",[20],"Device: Transcatheter Tricuspid Valve Annuloplasty",{"label":22,"type":10,"description":10,"interventionNames":23},"Device: Surgical Aortic Valve Replacement",[22],[25,28,30,32],{"type":26,"name":9,"description":9,"armGroupLabels":27,"otherNames":10},"DEVICE",[9],{"type":26,"name":14,"description":14,"armGroupLabels":29,"otherNames":10},[14],{"type":26,"name":18,"description":18,"armGroupLabels":31,"otherNames":10},[18],{"type":26,"name":33,"description":33,"armGroupLabels":34,"otherNames":10},"Surgical Aortic Valve Replacement",[22],[36],{"name":37,"role":38,"phone":39,"phoneExt":10,"email":40},"Guangyuan Song, MD, PhD","CONTACT","+86 13801120805","songgy_anzhen@vip.163.com",[42],{"facility":5,"status":10,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Beijing","Beijing Municipality","100029","China","CN",{"type":49,"coordinates":50},"Point",[51,52],116.39723,39.9075,{"lat":52,"lon":51},[55],{"name":37,"role":38,"phone":39,"phoneExt":10,"email":40},{"type":57,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100638048","active-post-market-surveillance-of-innovative-devices-for-valvular-heart-disease-100638048",false,"NCT07605624","Active Post-Market Surveillance of Innovative Devices for Valvular Heart Disease","An Active Post-Market Surveillance Study Assessing the Real-World Clinical Applicability, Long-Term Safety, and Effectiveness of Innovative Medical Devices for Valvular Heart Disease","Inclusion Criteria:\n\n* Patients with valvular heart disease (VHD) receiving treatment with prosthetic aortic valve replacement systems (transcatheter and surgical valves), transcatheter mitral valve edge-to-edge repair (TEER) systems, or transcatheter tricuspid valve annuloplasty systems\n* Age ≥ 18 years\n* Patients who voluntarily participate in the study and sign the informed consent form\n* Willing and able to comply with follow-up requirements","ALL","18 Years",{"count":68,"type":69},5500,"ESTIMATED","1 Year","OBSERVATIONAL","This prospective, multicenter, observational cohort study aims to establish a post-market registry framework to evaluate the real-world clinical applicability, long-term safety, and effectiveness of innovative heart valve devices in China.",[74,75,76,77],"Aortic Stenosis","Aortic Regurgitation","Mitral Regurgitation","Tricuspid Regurgitation","NOT_YET_RECRUITING","2026-05-18",{"date":81,"type":82},"2026-05-26","ACTUAL",{"date":84,"type":69},"2026-05-10",{"date":86,"type":69},"2029-01-31",{"name":5,"class":6},1]